Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Amneal Pharmaceuticals, Inc. Class A Common Stock

Healthcare US AMRX

13.75USD
0.23(1.70%)

Last update at 2026-06-05T20:00:00Z

Day Range

13.5513.88
LowHigh

52 Week Range

7.0215.42
LowHigh

Fundamentals

  • Previous Close 13.52
  • Market Cap4153.37M
  • Volume1276377
  • P/E Ratio59.18
  • Dividend Yield-%
  • EBITDA644.27M
  • Revenue TTM3018.76M
  • Revenue Per Share TTM9.63
  • Gross Profit TTM 1128.46M
  • Diluted EPS TTM0.22

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 139.21M -55.01300M -40.27000M -248.12700M 31.37M
Minority interest -55.87600M -43.01000M -35.27100M -125.24100M 9.55M
Net income 72.06M -116.88600M -83.99300M -254.78900M 20.17M
Selling general administrative 526.83M 442.04M 417.27M 400.43M 365.70M
Selling and marketing expenses - 34.40M 12.40M - -
Gross profit 1136.09M 1020.44M 863.87M 784.71M 768.97M
Reconciled depreciation 223.57M 236.19M 229.40M 240.18M 233.41M
Ebit 380.30M 203.58M 271.38M 206.46M 209.24M
Ebitda 603.87M 439.77M 500.78M 446.64M 442.64M
Depreciation and amortization 223.57M 236.19M 229.40M 240.18M 233.41M
Non operating income net other - - - 5.18M 14.97M
Operating income 423.09M 249.33M 204.37M 206.46M 209.24M
Other operating expenses 2595.67M 2544.63M 2189.23M 2023.38M 1899.76M
Interest expense 241.09M 258.60M 210.63M 158.38M 136.32M
Tax provision 11.28M 18.86M 8.45M 6.66M 11.20M
Interest income - - - - -
Net interest income -272.45600M -258.59500M -251.43400M -158.66800M -136.32500M
Extraordinary items - - - - -
Non recurring - - - 288.68M 35.28M
Other items - - - - -
Income tax expense 11.28M 18.86M 8.45M 6.66M 11.20M
Total revenue 3018.76M 2793.96M 2393.61M 2212.30M 2093.67M
Total operating expenses 713.00M 771.11M 659.50M 595.79M 575.07M
Cost of revenue 1882.67M 1773.52M 1529.74M 1427.60M 1324.70M
Total other income expense net -283.88100M -304.33900M -244.64400M -454.59100M -177.87000M
Discontinued operations - - - - -
Net income from continuing ops 127.93M -73.87600M -48.72200M -254.78900M 20.17M
Net income applicable to common shares - - - -129.98600M 10.62M
Preferred stock and other adjustments - - - 0.44M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 3678.28M 3501.45M 3472.57M 3799.34M 3939.66M
Intangible assets 563.50M 732.38M 890.42M 1096.09M 1166.92M
Earning assets - - - - -
Other current assets 54.13M 87.20M 91.20M 103.56M 110.22M
Total liab 3672.32M 3545.98M 3452.79M 3590.41M 3572.69M
Total stockholder equity -70.79400M -109.26700M 19.78M 183.98M 366.97M
Deferred long term liab - - - 2.21M 1.60M
Other current liab 605.39M 529.67M 475.40M 109.96M 47.86M
Common stock 3.15M 3.10M 3.07M 3.04M 3.01M
Capital stock 3.15M 3.10M 3.07M 3.04M 3.01M
Retained earnings -535.00500M -607.06200M -490.17600M -406.18300M -276.19700M
Other liab - - - 97.12M 48.52M
Good will 595.47M 597.44M 598.63M 598.85M 593.02M
Other assets - - - 17.63M 473.70M
Cash 310.87M 110.55M 91.54M 25.98M 247.79M
Cash and equivalents - - - - -
Total current liabilities 881.63M 1129.77M 846.60M 752.80M 677.24M
Current deferred revenue - - 398.41M - -
Net debt 2425.60M 2482.59M 2658.98M 2819.16M 2628.27M
Short term debt 21.58M 340.25M 227.62M 104.64M 46.04M
Short long term debt 6.76M 324.21M 213.12M 89.96M 30.61M
Short long term debt total 2736.47M 2593.14M 2750.52M 2845.14M 2876.06M
Other stockholder equity 571.79M 560.21M 539.24M 577.19M 664.98M
Property plant equipment - - - 469.81M 514.16M
Total current assets 1911.18M 1587.81M 1377.86M 1411.82M 1520.11M
Long term investments - - - - -
Net tangible assets - - - -1371.57600M -1382.69200M
Short term investments - 1.87M 2.20M - -
Net receivables 939.87M 775.73M 613.73M 742.29M 663.76M
Long term debt 2565.11M 2161.79M 2427.45M 2591.98M 2680.05M
Inventory 606.30M 612.45M 581.38M 530.74M 489.39M
Accounts payable 254.67M 259.84M 143.57M 538.20M 583.35M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - -114.44200M 6.63M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -110.72900M -65.51000M -32.34900M 9.94M -24.82700M
Additional paid in capital - - - - -
Common stock total equity - - - 3.04M 3.01M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -406.18300M -276.19700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 49.98M 24.21M 18.43M 103.22M 20.61M
Deferred long term asset charges - - - - -
Non current assets total 1767.10M 1913.64M 2094.71M 2387.52M 2419.56M
Capital lease obligations 117.17M 107.14M 109.95M 123.49M 127.35M
Long term debt total - - - 2591.98M 2680.05M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -62.99600M -69.18900M -174.30900M -194.18200M
Change to liabilities - - - 111.64M -46.28700M
Total cashflows from investing activities -112.26300M -62.99600M -69.18900M -174.30900M -194.18200M
Net borrowings 101.24M -185.11800M 22.65M 83.34M -1.00000M
Total cash from financing activities -31.53000M -211.79100M -212.57300M -106.62000M -138.12200M
Change to operating activities - - - 12.60M -17.02500M
Net income 72.06M -73.87600M -48.72200M -254.78900M 20.17M
Change in cash 194.52M 19.31M 63.88M -221.51200M -90.38200M
Begin period cash flow 118.42M 99.11M 35.23M 256.74M 347.12M
End period cash flow 312.94M 118.42M 99.11M 35.23M 256.74M
Total cash from operating activities 339.99M 295.10M 345.58M 65.10M 241.82M
Issuance of capital stock - - - - -
Depreciation 223.57M 236.19M 229.40M 240.18M 233.41M
Other cashflows from investing activities -42.20000M -14.65000M -22.38800M -127.90200M -146.45400M
Dividends paid - - - - -
Change to inventory -87.02600M -130.53000M -126.18200M -102.39600M -49.01500M
Change to account receivables -120.56600M -162.15500M 125.80M -79.71700M -23.62100M
Sale purchase of stock - -7.95200M -2.37800M -1.06000M 0.85M
Other cashflows from financing activities -59.75900M -26.67300M -235.22500M 15.99M -58.94300M
Change to netincome - - - 132.06M 112.48M
Capital expenditures 70.06M 74.99M 69.19M 90.59M 52.64M
Change receivables - - - -80.07100M -16.31000M
Cash flows other operating - - - 250.06M 211.58M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -215.82900M -90.48400M
Change in working capital -204.51600M -4.06800M -47.18600M -59.94500M -133.59300M
Stock based compensation 31.95M 27.77M 26.82M 31.85M 28.41M
Other non cash items 216.93M 109.08M 185.26M 107.81M 10.04M
Free cash flow 269.93M 220.11M 276.39M -25.49500M 189.18M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock		 0.23 1.70% 13.75 59.18 6.30 1.38 105.45 2.20 10.99
ZTS
Zoetis Inc		 -0.08 0.10% 79.44 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -1.13 3.48% 31.32 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -5.4 3.30% 158.31 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.13 0.32% 40.45 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Amneal Pharmaceuticals, Inc. Class A Common Stock

400 Crossing Boulevard, Bridgewater, NJ, United States, 08807

Key Executives

Name Title Year Born
Mr. Chirag K. Patel Co-Founder, Co-CEO, Pres & Director 1967
Mr. Chintu Patel R.Ph, R.Ph. Co-Founder, Co-CEO & Director 1972
Mr. Anastasios G. Konidaris Exec. VP & CFO 1967
Ms. Nikita Shah Exec. VP and Chief HR & Strategic Planning Officer 1978
Mr. Andrew S. Boyer Exec. VP & Chief Commercial Officer of Generics 1966
Mr. Anthony DiMeo Sr. Director of Investor Relations NA
Mr. Jason B. Daly Esq. Sr. VP, Chief Legal Officer & Corp. Sec. 1974
Mr. Sanjiv Patel Sr. VP of Operations NA
Dr. Nikunj Patel Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd NA
Mr. Sanjay Kumar Jain Ph.D. Pres of India Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.